Article
作者: St. Claire, Marisa ; Cai, Yingyun ; Adams, Ricky ; Ye, Chengjin ; Martínez-Sobrido, Luis ; de la Torre, Juan Carlos ; Kurtz, Jonathan ; Iwasaki, Masaharu ; Motooka, Daisuke ; Hart, Randy ; Burdette, Tracey ; Liu, David X. ; Postnikova, Elena N. ; Kuhn, Jens H. ; Cooper, Kurt ; Yu, Shuiqing
Lassa virus (LASV), the causative agent of Lassa fever, infects several hundred thousand people in Western Africa, resulting in many lethal Lassa fever cases. No U.S. Food and Drug Administration-licensed countermeasures are available to prevent or treat LASV infection. We describe the generation of a novel LASV live-attenuated vaccine candidate rLASV(IGR/S-S), which is based on the replacement of the large genomic segment noncoding intergenic region (IGR) with that of the small genome segment. rLASV(IGR/S-S) is less fit in cell culture than wild-type virus and does not cause clinical signs in inoculated guinea pigs. Importantly, rLASV(IGR/S-S) protects immunized guinea pigs against an otherwise lethal exposure to LASV.